Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00087490 |
To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
Condition | Intervention | Phase |
---|---|---|
Skin/Soft Tissue Infections Methicillin Resistant Staphylococcus Aureus (MRSA) |
Drug: linezolid Drug: vancomycin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus |
Enrollment: | 1077 |
Study Start Date: | October 2004 |
Study Completion Date: | July 2007 |
Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A5951002 |
Study First Received: | July 9, 2004 |
Last Updated: | July 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00087490 |
Health Authority: | United States: Food and Drug Administration |
Bacterial Infections Staphylococcal Infections Gram-Positive Bacterial Infections Methicillin |
Soft Tissue Infections Vancomycin Linezolid |
Protein Synthesis Inhibitors Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Infection Pharmacologic Actions |